瑞格列奈联合罗格列酮对糖尿病患者血清HbA1c、IL-6、TNF-α水平的影响

The Effect of Repaglinide Combined with Rosiglitazone on Serum HbA1c,IL-6 and TNF-αLevels in Diabetic Patients

目的探讨瑞格列奈联合罗格列酮对糖尿病患者血清HbA1c、IL-6、TNF-α水平的影响。方法选取2018年1月~2020年1月我院收治的糖尿病患者102例为研究对象,采用随机数字表法分为对照组和研究组,各51例,对照组应用瑞格列奈治疗,研究组在对照组基础上联合罗格列酮治疗,比较两组临床治疗总有效率、炎性指标水平、血脂指标水平、血糖水平以及不良反应发生情况。结果研究组总有效率为54.90%,高于对照组的37.30%,差异有统计学意义(P<0.05);研究组IL-6、CRP、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);研究组HbA1c、LDL-C、2hFPG水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);研究组FPG低于对照组,BMI高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为7.80%,低于对照组的23.50%,差异有统计学意义(P<0.05)。结论瑞格列奈联合罗格列酮治疗糖尿病效果确切,可减少不良反应,改善血清HbA1c、IL-6、TNF-α水平。

Objective To investigate the effect of repaglinide combined with rosiglitazone on serum HbA1c,IL-6 and TNF-αlevels in diabetic patients.Methods A total of 102 diabetic patients admitted to our hospital from January 2018 to January 2020 were selected as the research objects.The random number table was used to divide the control group and the study group,each with 51 cases.The control group was treated with repaglinide,and the study group was treated with rosiglitazone on the basis of the control group.The total effective rate and inflammation of the two groups were compared.Sex index level,blood lipid index level,blood sugar level and occurrence of adverse reactions.Results The total effective rate of the study group was 54.90%,which was higher than 37.30%of the control group,the difference was statistically significant(P<0.05);The levels of IL-6,CRP,and TNF-αin the study group were lower than those in the control group,the difference was statistically significant(P<0.05);The levels of HbA1c,LDL-C,and 2 hFPG in the study group were lower than those in the control group,and the levels of HDL-C were higher than those in the control group,the difference was statistically significant(P<0.05);The FPG of the study group was lower than that of the control group,and the BMI was higher than that of the control group,the difference was statistically significant(P<0.05);The incidence of adverse reactions in the study group was7.80%,which was lower than 23.50%in the control group,the difference was statistically significant(P<0.05).Conclusion Repaglinide combined with rosiglitazone has a definite effect in the treatment of diabetes.It can reduce adverse reactions and improve serum HbA1c,IL-6,and TNF-αlevels.